Tags

Type your tag names separated by a space and hit enter

Ginkgo biloba for prevention of dementia: a randomized controlled trial.
JAMA 2008; 300(19):2253-62JAMA

Abstract

CONTEXT

Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G. biloba on dementia incidence are lacking.

OBJECTIVE

To determine effectiveness of G. biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI).

DESIGN, SETTING, AND PARTICIPANTS

Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and 2008 with a median follow-up of 6.1 years. Three thousand sixty-nine community volunteers aged 75 years or older with normal cognition (n = 2587) or MCI (n = 482) at study entry were assessed every 6 months for incident dementia.

INTERVENTION

Twice-daily dose of 120-mg extract of G. biloba (n = 1545) or placebo (n = 1524).

MAIN OUTCOME MEASURES

Incident dementia and AD determined by expert panel consensus.

RESULTS

Five hundred twenty-three individuals developed dementia (246 receiving placebo and 277 receiving G. biloba) with 92% of the dementia cases classified as possible or probable AD, or AD with evidence of vascular disease of the brain. Rates of dropout and loss to follow-up were low (6.3%), and the adverse effect profiles were similar for both groups. The overall dementia rate was 3.3 per 100 person-years in participants assigned to G. biloba and 2.9 per 100 person-years in the placebo group. The hazard ratio (HR) for G. biloba compared with placebo for all-cause dementia was 1.12 (95% confidence interval [CI], 0.94-1.33; P = .21) and for AD, 1.16 (95% CI, 0.97-1.39; P = .11). G. biloba also had no effect on the rate of progression to dementia in participants with MCI (HR, 1.13; 95% CI, 0.85-1.50; P = .39).

CONCLUSIONS

In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI. Trial Registration clinicaltrials.gov Identifier: NCT00010803.

Authors+Show Affiliations

University of Pittsburgh, Pittsburgh, Pennsylvania, USA. dekosky@virginia.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19017911

Citation

DeKosky, Steven T., et al. "Ginkgo Biloba for Prevention of Dementia: a Randomized Controlled Trial." JAMA, vol. 300, no. 19, 2008, pp. 2253-62.
DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-62.
DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., ... Furberg, C. D. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300(19), pp. 2253-62. doi:10.1001/jama.2008.683.
DeKosky ST, et al. Ginkgo Biloba for Prevention of Dementia: a Randomized Controlled Trial. JAMA. 2008 Nov 19;300(19):2253-62. PubMed PMID: 19017911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ginkgo biloba for prevention of dementia: a randomized controlled trial. AU - DeKosky,Steven T, AU - Williamson,Jeff D, AU - Fitzpatrick,Annette L, AU - Kronmal,Richard A, AU - Ives,Diane G, AU - Saxton,Judith A, AU - Lopez,Oscar L, AU - Burke,Gregory, AU - Carlson,Michelle C, AU - Fried,Linda P, AU - Kuller,Lewis H, AU - Robbins,John A, AU - Tracy,Russell P, AU - Woolard,Nancy F, AU - Dunn,Leslie, AU - Snitz,Beth E, AU - Nahin,Richard L, AU - Furberg,Curt D, AU - ,, PY - 2008/11/20/pubmed PY - 2008/12/17/medline PY - 2008/11/20/entrez SP - 2253 EP - 62 JF - JAMA JO - JAMA VL - 300 IS - 19 N2 - CONTEXT: Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G. biloba on dementia incidence are lacking. OBJECTIVE: To determine effectiveness of G. biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI). DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and 2008 with a median follow-up of 6.1 years. Three thousand sixty-nine community volunteers aged 75 years or older with normal cognition (n = 2587) or MCI (n = 482) at study entry were assessed every 6 months for incident dementia. INTERVENTION: Twice-daily dose of 120-mg extract of G. biloba (n = 1545) or placebo (n = 1524). MAIN OUTCOME MEASURES: Incident dementia and AD determined by expert panel consensus. RESULTS: Five hundred twenty-three individuals developed dementia (246 receiving placebo and 277 receiving G. biloba) with 92% of the dementia cases classified as possible or probable AD, or AD with evidence of vascular disease of the brain. Rates of dropout and loss to follow-up were low (6.3%), and the adverse effect profiles were similar for both groups. The overall dementia rate was 3.3 per 100 person-years in participants assigned to G. biloba and 2.9 per 100 person-years in the placebo group. The hazard ratio (HR) for G. biloba compared with placebo for all-cause dementia was 1.12 (95% confidence interval [CI], 0.94-1.33; P = .21) and for AD, 1.16 (95% CI, 0.97-1.39; P = .11). G. biloba also had no effect on the rate of progression to dementia in participants with MCI (HR, 1.13; 95% CI, 0.85-1.50; P = .39). CONCLUSIONS: In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI. Trial Registration clinicaltrials.gov Identifier: NCT00010803. SN - 1538-3598 UR - https://www.unboundmedicine.com/medline/citation/19017911/Ginkgo_biloba_for_prevention_of_dementia:_a_randomized_controlled_trial_ L2 - https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2008.683 DB - PRIME DP - Unbound Medicine ER -